Abortion LateIVG-TardivesNCT07335939
Late-term Abortions Between 14 and 16 Weeks of Gestation: Comparison of Hemorrhagic Risks in Surgical vs. Medical Abortions
An observational study of Abortion Late, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Since the extension of the legal abortion limit to 16 weeks by the law of March 2, 2022, we must adapt our care to reduce the risks associated with this procedure. According to the French National Authority for Health (HAS), all abortions after 9 weeks of gestation should be performed surgically, but the French… Read more about this study
- Who is it for?
- Ages 18 to 40 years, women only
- Conditions the study is for
- Abortion Late
- How many people
- 50 participants
- Where
- 1 siteFrance
- Study dates
- 19 May 2025to 19 Jun 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- No healthy volunteers
- Adult
Study population: - Adult woman with single or multiple pregnancy and undergoing an abortion between 14 and 16 weeks of gestation at the Strasbourg University Hospital between March 2, 2022, and March 2, 2026
Who may be able to join
- Adult woman
- Single or multiple pregnancy
- Undergoing an abortion between 14 and 16 weeks of gestation at the Strasbourg University Hospital between March 2, 2022, and March 2, 2026
Who cannot join
- Missed Pregnancy
- Term < 14 Weeks of Gestation or > 16 Weeks of Gestation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service de Gynécologie-Obstétrique - CHU de Strasbourg - France
Strasbourg, 67091
Victor Gabriele, MD, 33 3 69 55 34 04, Victor.gabriele@chru-strasbourg.fr
Victor Gabriele, MD
About this study
Since the extension of the legal abortion limit to 16 weeks by the law of March 2, 2022, we must adapt our care to reduce the risks associated with this procedure. According to the French National Authority for Health (HAS), all abortions after 9 weeks of gestation should be performed surgically, but the French National College of Gynecologists and Obstetricians (CNGOF) indicates that each patient should have the choice of method regardless of the gestational age at the time of the abortion.
- Conditions
- Abortion Late
- Keywords
- Abortion Late, Ongoing single pregnancy, Ongoing multiple pregnancy
What is being measured
The primary outcome is the main question the study is designed to answer.
Bleeding (in cc)
Bleeding > 500 cc means a very large blood loss
Measured: During surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2026
- Study start19 May 2025
- Primary completionJun 2026 (estimated)
- Study completion19 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Abortion LateStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07335939
- Sponsor's protocol ID
- 9690
- Acronym
- IVG-Tardives
- Status last verified
- Jan 2026
- First submitted
- 2 Jan 2026
- Last updated
- 13 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Late-term Abortions Between 14 and 16 Weeks of Gestation: Comparison of Hemorrhagic Risks in Surgical vs. Medical Abortions
- ClinicalTrials.gov ID
- NCT07335939
- Acronym / sponsor ID
- IVG-Tardives / 9690
- Conditions
- Abortion Late
- Keywords
- Abortion Late, Ongoing single pregnancy, Ongoing multiple pregnancy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 19 May 2025 (actual)
- Primary completion
- Jun 2026 (estimated)
- Study completion
- 19 Jun 2026 (estimated)
- First posted
- 13 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Since the extension of the legal abortion limit to 16 weeks by the law of March 2, 2022, we must adapt our care to reduce the risks associated with this procedure. According to the French National Authority for Health (HAS), all abortions after 9 weeks of gestation should be performed surgically, but the French National College of Gynecologists and Obstetricians (CNGOF) indicates that each patient should have the choice of method regardless of the gestational age at the time of the abortion.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- - Adult woman with single or multiple pregnancy and undergoing an abortion between 14 and 16 weeks of gestation at the Strasbourg University Hospital between March 2, 2022, and March 2, 2026
Key inclusion criteria (3 listed)
- Adult woman
- Single or multiple pregnancy
- Undergoing an abortion between 14 and 16 weeks of gestation at the Strasbourg University Hospital between March 2, 2022, and March 2, 2026
Key exclusion criteria (2 listed)
- Missed Pregnancy
- Term < 14 Weeks of Gestation or > 16 Weeks of Gestation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Bleeding (in cc)
Time frame: During surgery
Bleeding > 500 cc means a very large blood loss
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2026.
Related trials for Abortion Late
Not yet recruiting
PS IVG : Psychosocial Determinants of Late-term Abortions (14-16 Weeks' Gestation) at Avignon Hospital
Psychosocial Health, Abortion
Not yet recruiting
Intracervical Block During Laminaria Insertion
Late Abortion, Dilation and Evacuation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Abortion Late, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Victor Gabrielle, MD (33 3 69 55 34 04, Victor.gabriele@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bleeding (in cc) (time frame: During surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.